These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34161198)

  • 1. Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis.
    Levander XA; Vega TA; Seaman A; Korthuis PT; Englander H
    Subst Abus; 2022; 43(1):245-252. PubMed ID: 34161198
    [No Abstract]   [Full Text] [Related]  

  • 2. "Sobriety equals getting rid of hepatitis C": A qualitative study exploring the interplay of substance use disorder and hepatitis C among hospitalized adults.
    Vega TA; Levander XA; Seaman A; Korthuis PT; Englander H
    J Subst Abuse Treat; 2021 Aug; 127():108337. PubMed ID: 34134860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilising an access to care integrated framework to explore the perceptions of hepatitis C treatment of hospital-based interventions among people who use drugs.
    Levander XA; Vega TA; Seaman A; Korthuis PT; Englander H
    Int J Drug Policy; 2021 Oct; 96():103356. PubMed ID: 34226111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
    Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
    BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project.
    Von den Hoff DW; Berden FAC; Drenth JPH; Schellekens AFA;
    Addict Sci Clin Pract; 2022 Nov; 17(1):67. PubMed ID: 36451175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
    Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
    BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis.
    Reed JR; Jordan AE; Perlman DC; Smith DJ; Hagan H
    Syst Rev; 2016 Jul; 5(1):110. PubMed ID: 27401499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs.
    Skeer MR; Ladin K; Wilkins LE; Landy DM; Stopka TJ
    Drug Alcohol Depend; 2018 Sep; 190():246-254. PubMed ID: 30071457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitated telemedicine for hepatitis C virus: Addressing challenges for improving health and life for people with opioid use disorder.
    Talal AH; Jaanimägi U; Dharia A; Dickerson SS
    Health Expect; 2023 Dec; 26(6):2594-2607. PubMed ID: 37641398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study.
    Valerio H; Alavi M; Law M; McManus H; Tillakeratne S; Bajis S; Martinello M; Matthews GV; Amin J; Janjua NZ; Krajden M; George J; Degenhardt L; Grebely J; Dore GJ
    Clin Infect Dis; 2021 Dec; 73(11):2037-2044. PubMed ID: 34107022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When "the Cure" Is the Risk: Understanding How Substance Use Affects HIV and HCV in a Layered Risk Environment in San Juan, Puerto Rico.
    Hernández D; Castellón PC; Fernández Y; Torres-Cardona FA; Parish C; Gorshein D; Vargas Vidot J; Miranda de Leon S; Rodriguez A; Santana Bagur J; Feaster DJ; Schackman BR; Metsch LR
    Health Educ Behav; 2017 Oct; 44(5):748-757. PubMed ID: 28891344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Risk Prediction Tool to Identify People at Greater Risk of Having Hepatitis C among Drug Users.
    Huang G; Cheng W; Xu Y; Yang J; Jiang J; Pan X; Zhou X; Jiang J; Chai C
    Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV point-of-care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy.
    Persico M; Masarone M; Aglitti A; Armenante C; Giordano A; Guardiola A; Raimondi G; Contaldi C; Nigro C; Marena G; De Luna A
    Liver Int; 2019 Oct; 39(10):1845-1851. PubMed ID: 31169953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.
    Socías ME; Ti L; Dong H; Shoveller J; Kerr T; Montaner J; Milloy MJ
    HIV Med; 2017 Oct; 18(9):647-654. PubMed ID: 28294492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single site study to investigate the current prevalence of anti-hepatitis C virus antibody among substance use disorder patients in Hiroshima-Insufficient testing and diagnosis.
    Kagaya A; Nagaoki Y; Shimura S; Kawana K; Chayama K
    Neuropsychopharmacol Rep; 2023 Dec; 43(4):521-531. PubMed ID: 37193604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences of Hope after Treatment of Hepatitis C Infection-A Qualitative Study.
    Sælør KT; Carlsen SL; Fadnes LT; Lorås L
    Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.
    Norton BL; Fleming J; Bachhuber MA; Steinman M; DeLuca J; Cunningham CO; Johnson N; Laraque F; Litwin AH
    Int J Drug Policy; 2017 Sep; 47():196-201. PubMed ID: 28811158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.